FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Moritz

Research Profile

Anatomy

Physiology

Living Beings

Disorders

Multiple Myeloma

Chemicals & Drugs

Procedures

Concepts & Ideas

Survival Analysis

Co-author Network

Publications

TOP 3
Semra Aydin; Alexander Carpinteiro; Ulrich Dührsen; Peter Ebeling; Lewin Eisele; Joachim R Göthert; Florian Grabellus; Maher Hanoun; Michael Möllmann; Thomas Moritz; Holger Nückel; Ali Sak; Jan Dürig
Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model.
Philipp Schütt; K Zimmermann; C Derks; Peter Ebeling; Anja Welt; Miriam Poser; J Hense; Klaus Metz; J Anhuf; M Sandmann; M Neise; Thomas Moritz; Martin Stuschke; N Niederle; Siegfried Seeber; Mohammad Resa Nowrousian
Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
Veronika Kleff; Ursula R Sorg; Carsten Bury; Takuji Suzuki; Ina Rattmann; Moran Jerabek-Willemsen; Christopher Poremba; Michael Flasshove; Bertram Opalka; Bruce Trapnell; Uta Dirksen; Thomas Moritz
Gene therapy of beta(c)-deficient pulmonary alveolar proteinosis (beta(c)-PAP): studies in a murine in vivo model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Moritz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Semra Aydin; Alexander Carpinteiro; Ulrich Dührsen; Peter Ebeling; Lewin Eisele; Joachim R Göthert; Florian Grabellus; Maher Hanoun; Michael Möllmann; Thomas Moritz; Holger Nückel; Ali Sak; Jan Dürig
Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model.
European journal of haematology 2011;87(1):10-9.
2009: Philipp Schütt; K Zimmermann; C Derks; Peter Ebeling; Anja Welt; Miriam Poser; J Hense; Klaus Metz; J Anhuf; M Sandmann; M Neise; Thomas Moritz; Martin Stuschke; N Niederle; Siegfried Seeber; Mohammad Resa Nowrousian
Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
Journal of cancer research and clinical oncology 2009;135(3):459-66.
2008: Veronika Kleff; Ursula R Sorg; Carsten Bury; Takuji Suzuki; Ina Rattmann; Moran Jerabek-Willemsen; Christopher Poremba; Michael Flasshove; Bertram Opalka; Bruce Trapnell; Uta Dirksen; Thomas Moritz
Gene therapy of beta(c)-deficient pulmonary alveolar proteinosis (beta(c)-PAP): studies in a murine in vivo model.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(4):757-64.
2008: Philipp Schütt; Vera Rebmann; Dieter Brandhorst; Johannes Wiefelspütz; Peter Ebeling; Bertram Opalka; Siegfried Seeber; Mohammad R Nowrousian; Thomas Moritz; Hans Grosse-Wilde
The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
Human immunology 2008;69(2):79-87.
2008: Peter Ebeling; Lewin Eisele; Philipp Schuett; Sebastian Bauer; Jochen Schuette; Thomas Moritz; Siegfried Seeber; Michael Flasshove
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Onkologie 2008;31(1-2):11-6.
2007: Jan Dürig; Peter Ebeling; Florian Grabellus; Ursula R Sorg; Michael Möllmann; Philipp Schütt; Joachim Göthert; Ludger Sellmann; Siegfried Seeber; Michael Flasshove; Ulrich Dührsen; Thomas Moritz
A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease.
Cancer research 2007;67(18):8653-61.
2007: Anja Welt; Philipp Schütt; Cordula Derks; Peter Ebeling; Siemke Müller; Klaus Metz; Jürgen Anhuf; Thomas Moritz; Siegfried Seeber; Mohammad Resa Nowrousian
Long-term results of a phase-I/II study of sequential high-dose chemotherapy with autologous stem cell transplantation in the initial treatment of aggressive non-Hodgkin's lymphoma.
Tumori 2007;93(5):409-16.
2007: Ursula R Sorg; Veronika Kleff; Sepideh Fanaei; Alexandra Schumann; Michael Moellmann; Bertram Opalka; Jürgen Thomale; Thomas Moritz
O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues.
DNA repair 2007;6(8):1197-209.
2007: Vera Rebmann; Philipp Schütt; Dieter Brandhorst; Bertram Opalka; Thomas Moritz; Mohammad Resa Nowrousian; Hans Grosse-Wilde
Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
Clinical immunology (Orlando, Fla.) 2007;123(1):114-20.
2007: Peter Ebeling; P Bach; Ursula R Sorg; A Schneider; Tanja Trarbach; Dagmar Dilloo; Helmut Hanenberg; S Niesert; Siegfried Seeber; Thomas Moritz; Michael Flasshove
Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.
Journal of cancer research and clinical oncology 2007;133(3):199-209.
2007: Philipp Schütt; J Passon; Peter Ebeling; Anja Welt; Siemke Müller; Klaus Metz; Thomas Moritz; Siegfried Seeber; Mohammad Resa Nowrousian
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
European journal of haematology 2007;78(2):93-101.
2007: Ina Rattmann; Veronika Kleff; Anja Feldmann; Carsten Ludwig; Ursula R Sorg; Bertram Opalka; Thomas Moritz; Michael Flasshove
Reliable generation of stable high titer producer cell lines for gene therapy.
Intervirology 2007;50(3):197-203.
2007: L Eisele; Ludger Klein-Hitpass; N Chatzimanolis; Bertram Opalka; Tanja Boes; Siegfried Seeber; Thomas Moritz; Michael Flasshove
Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia.
Acta haematologica 2007;117(1):8-15.
2006: Ina Rattmann; Veronika Kleff; Ursula R Sorg; Walter Bardenheuer; Annette Brueckner; Ralf A Hilger; Bertram Opalka; Siegfried Seeber; Michael Flasshove; Thomas Moritz
Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.
Blood 2006;108(9):2965-71.
2006: Philipp Schütt; Dieter Brandhorst; Werner Stellberg; Miriam Poser; Peter Ebeling; Siemke Müller; Ulrike Buttkereit; Bertram Opalka; Monika Lindemann; Hans Grosse-Wilde; Siegfried Seeber; Thomas Moritz; Mohammad Resa Nowrousian
Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
Leukemia & lymphoma 2006;47(8):1570-82.
2006: Tomke U Bracker; Bernd Giebel; Jan Spanholtz; Ursula R Sorg; Ludger Klein-Hitpass; Thomas Moritz; Jürgen Thomale
Stringent regulation of DNA repair during human hematopoietic differentiation: a gene expression and functional analysis.
Stem cells (Dayton, Ohio) 2006;24(3):722-30.
2005: Mohammad Resa Nowrousian; Dieter Brandhorst; Christiane Sammet; Michaela Kellert; Rainer Daniels; Philipp Schuett; Miriam Poser; Siemke Mueller; Peter Ebeling; Anja Welt; Arthur R Bradwell; Ulrike Buttkereit; Bertram Opalka; Michael Flasshove; Thomas Moritz; Siegfried Seeber
Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8706-14.
2005: Walter Bardenheuer; K Lehmberg; Ina Rattmann; A Brueckner; A Schneider; Ursula R Sorg; Siegfried Seeber; Thomas Moritz; Michael Flasshove
Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells.
Leukemia 2005;19(12):2281-8.
2005: Philipp Schütt; Peter Ebeling; Ulrike Buttkereit; Dieter Brandhorst; Bertram Opalka; Miriam Poser; Siemke Müller; Michael Flasshove; Thomas Moritz; Siegfried Seeber; Mohammad Resa Nowrousian
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Annals of hematology 2005;84(9):594-600.
2005: Philipp Schütt; Ulrike Buttkereit; Dieter Brandhorst; Monika Lindemann; Sven Schmiedl; Hans Grosse-Wilde; Siegfried Seeber; Mohammad Resa Nowrousian; Bertram Opalka; Thomas Moritz
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
Cancer immunology, immunotherapy : CII 2005;54(5):506-12.
2005: Monika Lindemann; Philipp Schuett; Thomas Moritz; Hellmut D Ottinger; Bertram Opalka; Siegfried Seeber; Mohammad Resa Nowrousian; Hans Grosse-Wilde
Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation.
Leukemia 2005;19(3):490-2.
2005: Claudia Strehblow; Maj Schuster; Thomas Moritz; Hans-Christoph Kirch; Bertram Opalka; Jean-Bernhard Petri
Monoclonal antibody-polyethyleneimine conjugates targeting Her-2/neu or CD90 allow cell type-specific nonviral gene delivery.
Journal of controlled release : official journal of the Controlled Release Society 2005;102(3):737-47.
2005: Siemke Müller; Philipp Schütt; Peter Bojko; Mohammad Resa Nowrousian; J Hense; Siegfried Seeber; Thomas Moritz
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Annals of hematology 2005;84(2):110-4.
2005: Philipp Schütt; Peter Ebeling; Ulrike Buttkereit; Dieter Brandhorst; Bertram Opalka; M Hoiczyk; Michael Flasshove; J Hense; Peter Bojko; Klaus Metz; Thomas Moritz; Siegfried Seeber; Mohammad Resa Nowrousian
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
European journal of haematology 2005;74(1):40-6.
2003: Roland Meisel; Walter Bardenheuer; Claudia Strehblow; Ursula R Sorg; Ahmet H Elmaagacli; Siegfried Seeber; Michael Flasshove; Thomas Moritz
Efficient protection from methotrexate toxicity and selection of transduced human hematopoietic cells following gene transfer of dihydrofolate reductase mutants.
Experimental hematology 2003;31(12):1215-22.
2003: Michael Flasshove; Thomas Moritz; Walter Bardenheuer; Siegfried Seeber
Hematoprotection by transfer of drug-resistance genes.
Acta haematologica 2003;110(2-3):93-106.
2003: Mohammad Resa Nowrousian; S Waschke; Peter Bojko; Anja Welt; Philipp Schuett; Peter Ebeling; Michael Flasshove; Thomas Moritz; J Schuette; Siegfried Seeber
Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14 Suppl 1():i29-36.
2002: Michael Jansen; Ursula R Sorg; Susanne Ragg; Michael Flasshove; Siegfried Seeber; David A Williams; Thomas Moritz
Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
Cancer gene therapy 2002;9(9):737-46.
2002: Claudia Buschfort-Papewalis; Thomas Moritz; Bernd Liedert; Jürgen Thomale
Down-regulation of DNA repair in human CD34(+) progenitor cells corresponds to increased drug sensitivity and apoptotic response.
Blood 2002;100(3):845-53.
2001: M Jansen; Walter Bardenheuer; Ursula R Sorg; Siegfried Seeber; Michael Flasshove; Thomas Moritz
Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones.
European journal of haematology 2001;67(1):2-13.
2001: Thomas Moritz; D A Williams
Marrow protection - transduction of hematopoietic cells with drug resistance genes.
Cytotherapy 2001;3(2):67-84.
2000: Michael Flasshove; Walter Bardenheuer; A Schneider; G Hirsch; P Bach; C Bury; Thomas Moritz; Siegfried Seeber; Bertram Opalka
Type and position of promoter elements in retroviral vectors have substantial effects on the expression level of an enhanced green fluorescent protein reporter gene.
Journal of cancer research and clinical oncology 2000;126(7):391-9.
2000: Tanja Trarbach; S Greifenberg; Walter Bardenheuer; Ahmet H Elmaagacli; H Hirche; Michael Flasshove; Siegfried Seeber; Thomas Moritz
Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments.
Cytotherapy 2000;2(6):429-38.
1999: Michael Flasshove; Werner Frings; JK Schröder; Thomas Moritz; Jochen Schütte; Siegfried Seeber
Transfer of the cytidine deaminase cDNA into hematopoietic cells.
Leukemia research 1999;23(11):1047-53.
1999: Peter Bojko; N Nowak; Thomas Moritz; Michael Flasshove; Andreas Harstrick; Siegfried Seeber
Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells.
Journal of clinical apheresis 1999;14(2):57-62.